Ignite Creation Date:
2025-12-25 @ 4:52 AM
Ignite Modification Date:
2026-04-22 @ 7:32 AM
Study NCT ID:
NCT02736318
Status:
TERMINATED
Last Update Posted:
2022-01-14
First Post:
2016-04-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
OD-PHOENIX in Talus Osteochondral Lesion
Sponsor:
TBF Genie Tissulaire
Organization:
Study Overview
Official Title:
Treatment of Osteochondral Lesion of Talus With Processed Osteochondral Allograft
Status:
TERMINATED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low accrual rate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TBF3
Brief Summary:
Treatment of osteochondral lesion of Talus with a devitalized viro-inativated sterile osteochondral graft. To avoid having to harvest autograft material from the knee, a processed allogeneic osteochondral can be used instead autograft. The surgical technique is to implant in the osteochondral defect one to three products in the defect.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: